The management of multiple myeloma presents many clinical challenges. The additional layer of complication COVID-19 places on patients and clinicians is a very real concern. Typically presenting with reduced immunity to viral infection, patients with multiple myeloma are at greater risk of COVID-19.
In this podcast, Prof. Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the adversities being faced due to the coronavirus pandemic, risk factors, and how negative outcomes can be minimized. Specifically, Prof. Mohty discusses the ways hospital visits can be reduced and treatments amended to reduce risk while still maintaining efficacy.
The post Myeloma management in the COVID-19 era appeared first on VJHemOnc.
